[Interpretation of treatment for newly diagnosed multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
作者信息
Liu J R, Li J
机构信息
Department of Hematology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
出版信息
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):465-469. doi: 10.3760/cma.j.cn112138-20220309-00162.
Abstract
摘要
相似文献
1
[Interpretation of treatment for newly diagnosed multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):465-469. doi: 10.3760/cma.j.cn112138-20220309-00162.
2
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].中国多发性骨髓瘤诊断与治疗指南（2015年修订版）：复发/难治性多发性骨髓瘤治疗解读
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):93-4. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004.
3
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of diagnosis].《中国多发性骨髓瘤诊治指南（2015年修订版）：诊断解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):91-2. doi: 10.3760/cma.j.issn.0578-1426.2016.02.002.
4
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of initial treatment].《中国多发性骨髓瘤诊治指南（2015年修订版）：初始治疗解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):92-3. doi: 10.3760/cma.j.issn.0578-1426.2016.02.003.
5
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of response criteria].《中国多发性骨髓瘤诊治指南（2015年修订版）：疗效标准解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):94-6. doi: 10.3760/cma.j.issn.0578-1426.2016.02.005.
6
[Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].[中国多发性骨髓瘤诊断与治疗指南（2022年修订版）中多发性骨髓瘤诊断的解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):463-465. doi: 10.3760/cma.j.cn112138-20220316-00182.
7
[Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].[《中国多发性骨髓瘤诊断与治疗指南（2022年修订版）》中复发/难治性多发性骨髓瘤患者的治疗解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):469-473. doi: 10.3760/cma.j.cn112138-20220414-00278.
8
[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].《解读<中国多发性骨髓瘤诊断与治疗指南（2020年修订版）>中微小残留病监测用于疗效评估》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.
9
[The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].中国多发性骨髓瘤诊断与治疗指南（2017年修订版）
Zhonghua Nei Ke Za Zhi. 2017 Nov 1;56(11):866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021.
10
[Best wishes to the guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)].[祝《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》顺利]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):329-331. doi: 10.3760/cma.j.cn112138-20200309-00208.
Zotero 插件